Media

Media

Recent News

  • Avivagen Announces Update on Private Placement Process

    Ottawa, ON /Business Wire/ January 20, 2020 / — Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to provide an update on the status of its previously announced non-brokered private placement (the “Offering”) of …Read More

  • Avivagen Inc. Commences Trading on the OTCQB® Venture Market in the U.S.

    Ottawa, ON / Business Wire / January 08, 2020 / – Avivagen Inc. (TSXV:VIV, OTCQB: VIVXF) (“Avivagen”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to announce that it has qualified to trade its common shares in the United States on …Read More

  • Avivagen Announces Closing of $1.25 Million Private Placement

    Ottawa, ON /Business Wire/ January 3, 2020 / — Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to announce the successful completion of a non-brokered private placement (the “Offering”), issuing 2,500,000 units (the “Units”) …Read More

  • Avivagen Inc. Announces Results for Fiscal Year Ending October 31, 2019

    Ottawa, ON /Business Wire/ December 19, 2019 / — Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”) today reported its audited financial results for the year ended October 31, 2019. Unless otherwise noted, all figures are in Canadian currency. The Company’s audited year end Financial Statements and its Management’s Discussion and Analysis for the year ended …Read More

  • Agreement with COFCO Biotechnology Sets Stage for Avivagen to Secure OxC-betaTM Livestock Approval in China

    Ottawa, ON / Business Wire / December 17, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”) has announced that it has entered into an agreement with the research subsidiary of COFCO Biotechnology  Co. Ltd.  (“COFCO”) pursuant to which COFCO will assist Avivagen with the approval process necessary to enter the Chinese market. With over 12,000 employees, …Read More

View All News Releases

Media Coverage

  • VICTAM Asia

    Avivagen CEO Interviewed at VICTAM Asia 2018 Conference

    Avivagen recently debuted at the VICTAM ASIA 2018 Conference in Bangkok, Thailand.

  • CEO Kym Anthony Interviewed by Uptick

    CEO Kym Anthony was interviewed by the penny stock news and trends podcast, Uptick Newswire.

    I think if people keep their eyes on the size of the prize, [they’ll see] the livestock market is in the billions of dollars; our share of that would be in the hundreds of millions if we roll out successfully. The human market is untouched. The companion animal market is also big. We’ve spent years proving it works; everyone agrees it works. Now is the time to roll it out commercially.

  • CTV: Growing resistance to antibiotics fuels market for alternative solutions

    CTV NEWS, TORONTO – A hundred years ago, a small wound could result in death if an infection spread. That could become reality again as the world threatens to return to a pre-antibiotic era due to antibiotic resistance.

    Some have pointed to the widespread use of antibiotics in livestock feed as a culprit, resulting in urgent calls to quell their use and find alternatives.

View All Media Coverage